Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 14, 2016. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions were executed on October 13, 2016, on the London Stock Exchange.
Key Financial Metrics
The filing does not report company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Instrument | Transaction Type | Price per Share | Total Volume |
|---|---|---|---|
| Ordinary Shares (25 pence each) | Acquisition via Dividend Re-investment | £17.0491 | 328 shares |
Note: The total volume of 328 shares is the aggregate of individual transactions listed in the filing.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It reports routine compliance notifications for share acquisitions resulting from the re-investment of dividends paid on October 13, 2016, under the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 11 senior executives, including the CEO (Sir Andrew Witty), CFO (Mr S Dingemans), and CEO Designate (Ms E Walmsley).
- Share Price: The execution price for all transactions was £17.0491 per share.
- Regulatory Context: These are initial notifications required under securities regulations for PDMRs.